The biopharmaceutical company’s stock market provides a remarkable tends. During the week, the worth directly moved to forward from its low of $2.4900 to its current price of $3.3200 by composing over 33% growth. Today’s news contributed to a more significant increase in the price of RedHill shares. And today, the company announced a new study called the Pitfalls of physician-directed treatment of Helicobacter pylori.
This study evaluated prescribing regimens and associated treatment cure rates for subjects with persistent H. pylori infection after participating in two phases 3 clinical trials. The study also analyzed the CYP2C19 genotype in subjects prescribed triple therapy based on clarithromycin.
Moreover, H. pylori is a bacterial infection that impacts nearly 35% of the population in the United States, with an estimated two million individuals treated each year. More than half of the world’s population has H. pylori infection, which is classed as a Group 1 carcinogen by the WHO. H.pylori, which showed that the most frequently chosen treatment methods for therapy conducted by a doctor were triple clarithromycin-based regimens, which account for more than 80% of prescriptions. Overall, it says that the study highlights the need to change the prescribing habits of H.pylori, given the increasing resistance and suboptimal eradication rates observed with clarithromycin-based regimens.